A team of researchers from the Personalized Medicine Coalition (PMC), Health Advances, and Syapse today announced the publication of a new peer-reviewed study showing that institutions with higher scores on a multi-factorial assessment of personalized medicine integration are more consistently matching cancer patients with genetically guided treatment options. The findings suggest that by boosting their institutions’ personalized medicine integration scores, health system executives and clinicians in the United States can improve the quality of care they are able to provide to their patients.

The study, titled “Improvements in Clinical Cancer Care Associated with Integration of Personalized Medicine,” was published in the Journal of Personalized Medicine. Its findings are based on data provided by six institutions within three regional health systems.

PMC Senior Vice President for Science Policy Daryl Pritchard, Ph.D., who co-authored the study, summarized the broader significance of its findings in an editorial for Inside Precision Medicine magazine this morning.

“The publication of this study adds to the body of evidence suggesting that a health system’s adoption of personalized medicine in clinical settings improves the quality of care delivered to its patients,” Pritchard said.